To evaluate the tolerability and clinical effects of subcutaneous (SC) levetiracetam for the
treatment of epileptic seizures in a palliative care setting, we conducted a retrospective chart …

Objectives: The aim of this study is to report the results of a second cycle audit of the use of
subcutaneous levetiracetam (Keppra®) and an updated literature review of management of …

Background: Seizure control is challenging in the palliative care setting. Subcutaneous (SC)
levetiracetam (LEV) is currently an off-label route of administration and effectiveness …

Objectives To report the results of a combined case series analysis of subcutaneous
levetiracetam (Keppra) for the management of seizures in palliative care patients. Methods A …

Background: Antiepileptic drugs are usually administere dorally, but alternative routes of
drug delivery may be required when oral administration is not feasible. Objective: The …

Purpose: The primary objective of this placebo‐controlled study was to evaluate the safety
and tolerability of levetiracetam (LEV) administered intravenously (IV) at higher doses and/or …

We report the case of a man who developed seizures on a background of recurrent
metastatic squamous cell carcinoma with intracranial involvement. Initial seizure control with …

Objectives–To evaluate the efficacy and safety of long‐term add‐on treatment with
levetiracetam 1,000–4,000 mg/day. Patients and methods–In this multicenter, open‐label …

Abstract Background and Objective Levetiracetam is available in China as adjunctive oral
therapy for partial-onset seizures. This study was conducted to evaluate the bioequivalence …

Levetiracetam, an antiepileptic drug, is used worldwide as an adjunctive treatment for partial‐
onset seizures. The availability of a new oral solution formulation would provide an …